<DOC>
	<DOCNO>NCT00792571</DOCNO>
	<brief_summary>This open-label extension study patient participate BPS-MR-PAH-201 study .</brief_summary>
	<brief_title>An Open-Label Extension BPS-MR-PAH-201 Pulmonary Arterial Hypertension ( PAH ) Patients</brief_title>
	<detailed_description>This open-label study patient participate BPS-MR-PAH-201 study volunteer continue treatment PAH BPS-MR tablet . Each patient return clinic follow enrollment study 3 , 6 , 12 month , annually thereafter assessment . Currently enrol patient may invite participate optional four time daily ( QID ) dose substudy BPS-MR total daily dose BPS-MR achieve previously main study . Patients return clinic baseline visit , week 12 , follow visit schedule provide BPS-MR-PAH-202 main study .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Beraprost</mesh_term>
	<mesh_term>Epoprostenol</mesh_term>
	<criteria>Patients remain study drug complete assessment Treatment Phase Study BPSMRPAH201 eligible study . Female patient must either physiologically incapable childbearing practice acceptable method birth control ( e.g . approve hormonal contraceptive , barrier method , condom diaphragm , use spermicide , intrauterine device ) . Patients discontinue study drug previous study ( BPSMRPAH201 ) reason ( e.g . treatment related adverse event ) eligible entry study . Patients pregnant lactate excluded participation openlabel extension .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>